vs
WARRIOR MET COAL, INC.（HCC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
WARRIOR MET COAL, INC.的季度营收约是Orthofix Medical Inc.的2.1倍（$458.6M vs $219.9M），WARRIOR MET COAL, INC.净利率更高（15.8% vs -1.0%，领先16.8%），WARRIOR MET COAL, INC.同比增速更快（52.1% vs 2.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 7.5%）
Warrior Met Coal（股票代码HCC）是总部位于美国的矿业企业，主营高品质冶金煤的开采与供应，其产品是钢铁制造的核心原材料，主要服务北美、欧洲、亚洲地区的钢铁生产商及工业客户。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
HCC vs OFIX — 直观对比
营收规模更大
HCC
是对方的2.1倍
$219.9M
营收增速更快
HCC
高出50.1%
2.0%
净利率更高
HCC
高出16.8%
-1.0%
两年增速更快
OFIX
近两年复合增速
7.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $458.6M | $219.9M |
| 净利润 | $72.3M | $-2.2M |
| 毛利率 | 36.7% | 71.1% |
| 营业利润率 | 17.3% | 0.2% |
| 净利率 | 15.8% | -1.0% |
| 营收同比 | 52.1% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $1.37 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HCCOFIX
| Q1 26 | $458.6M | — | ||
| Q4 25 | $384.0M | $219.9M | ||
| Q3 25 | $328.6M | $205.6M | ||
| Q2 25 | $297.5M | $203.1M | ||
| Q1 25 | $299.9M | $193.6M | ||
| Q4 24 | $297.5M | $215.7M | ||
| Q3 24 | $327.7M | $196.6M | ||
| Q2 24 | $396.5M | $198.6M |
净利润HCCOFIX
| Q1 26 | $72.3M | — | ||
| Q4 25 | $23.0M | $-2.2M | ||
| Q3 25 | $36.6M | $-22.8M | ||
| Q2 25 | $5.6M | $-14.1M | ||
| Q1 25 | $-8.2M | $-53.1M | ||
| Q4 24 | $1.1M | $-29.1M | ||
| Q3 24 | $41.8M | $-27.4M | ||
| Q2 24 | $70.7M | $-33.4M |
毛利率HCCOFIX
| Q1 26 | 36.7% | — | ||
| Q4 25 | 29.5% | 71.1% | ||
| Q3 25 | 27.1% | 72.2% | ||
| Q2 25 | 23.9% | 68.7% | ||
| Q1 25 | 18.1% | 62.8% | ||
| Q4 24 | 23.1% | 69.0% | ||
| Q3 24 | 29.3% | 68.7% | ||
| Q2 24 | 34.1% | 67.8% |
营业利润率HCCOFIX
| Q1 26 | 17.3% | — | ||
| Q4 25 | 9.0% | 0.2% | ||
| Q3 25 | 6.3% | -8.3% | ||
| Q2 25 | 2.6% | -7.9% | ||
| Q1 25 | -5.8% | -25.2% | ||
| Q4 24 | -1.4% | -5.3% | ||
| Q3 24 | 11.9% | -9.6% | ||
| Q2 24 | 17.9% | -12.5% |
净利率HCCOFIX
| Q1 26 | 15.8% | — | ||
| Q4 25 | 6.0% | -1.0% | ||
| Q3 25 | 11.1% | -11.1% | ||
| Q2 25 | 1.9% | -6.9% | ||
| Q1 25 | -2.7% | -27.4% | ||
| Q4 24 | 0.4% | -13.5% | ||
| Q3 24 | 12.7% | -13.9% | ||
| Q2 24 | 17.8% | -16.8% |
每股收益（稀释后）HCCOFIX
| Q1 26 | $1.37 | — | ||
| Q4 25 | $0.43 | $-0.05 | ||
| Q3 25 | $0.70 | $-0.57 | ||
| Q2 25 | $0.11 | $-0.36 | ||
| Q1 25 | $-0.16 | $-1.35 | ||
| Q4 24 | $0.02 | $-0.76 | ||
| Q3 24 | $0.80 | $-0.71 | ||
| Q2 24 | $1.35 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $233.2M | $82.0M |
| 总债务越低越好 | $154.4M | — |
| 股东权益账面价值 | — | $450.0M |
| 总资产 | $2.8B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HCCOFIX
| Q1 26 | $233.2M | — | ||
| Q4 25 | $300.0M | $82.0M | ||
| Q3 25 | $336.3M | $62.9M | ||
| Q2 25 | $383.3M | $65.6M | ||
| Q1 25 | $454.9M | $58.0M | ||
| Q4 24 | $491.5M | $83.2M | ||
| Q3 24 | $583.2M | $30.1M | ||
| Q2 24 | $709.0M | $26.4M |
总债务HCCOFIX
| Q1 26 | $154.4M | — | ||
| Q4 25 | $154.3M | — | ||
| Q3 25 | $154.1M | $157.2M | ||
| Q2 25 | $153.9M | $157.0M | ||
| Q1 25 | $153.8M | $156.9M | ||
| Q4 24 | $153.6M | $157.0M | ||
| Q3 24 | $153.5M | $118.5M | ||
| Q2 24 | $153.3M | $118.0M |
股东权益HCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $2.1B | $450.0M | ||
| Q3 25 | $2.1B | $442.5M | ||
| Q2 25 | $2.1B | $458.3M | ||
| Q1 25 | $2.1B | $458.3M | ||
| Q4 24 | $2.1B | $503.1M | ||
| Q3 24 | $2.1B | $525.9M | ||
| Q2 24 | $2.0B | $546.0M |
总资产HCCOFIX
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $850.6M | ||
| Q3 25 | $2.7B | $832.6M | ||
| Q2 25 | $2.6B | $837.2M | ||
| Q1 25 | $2.6B | $823.1M | ||
| Q4 24 | $2.6B | $893.3M | ||
| Q3 24 | $2.6B | $867.9M | ||
| Q2 24 | $2.6B | $882.0M |
负债/权益比HCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.07× | 0.36× | ||
| Q2 25 | 0.07× | 0.34× | ||
| Q1 25 | 0.07× | 0.34× | ||
| Q4 24 | 0.07× | 0.31× | ||
| Q3 24 | 0.07× | 0.23× | ||
| Q2 24 | 0.07× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流HCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $76.1M | $27.7M | ||
| Q3 25 | $104.7M | $12.4M | ||
| Q2 25 | $37.5M | $11.6M | ||
| Q1 25 | $10.9M | $-18.4M | ||
| Q4 24 | $54.2M | $23.7M | ||
| Q3 24 | $62.2M | $11.7M | ||
| Q2 24 | $147.0M | $9.0M |
自由现金流HCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K |
自由现金流率HCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% |
资本支出强度HCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% |
现金转化率HCCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 3.31× | — | ||
| Q3 25 | 2.86× | — | ||
| Q2 25 | 6.70× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 47.68× | — | ||
| Q3 24 | 1.49× | — | ||
| Q2 24 | 2.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HCC
| Sales | $448.5M | 98% |
| Other revenues | $10.1M | 2% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
